Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Hisamitsu Seeks Japan Approval for Allergic Rhinitis Tape Treatment
December 20, 2016
- Shionogi Hooks Up with Purdue on Naldemedine Commercialization in US
December 20, 2016
- Concerns Expressed Over High Cost of Regenerative Medicines; As with Opdivo, “Bound to Become Issue Again”
December 20, 2016
- Teva Takeda Recalls Dalteparin “Taiyo”
December 20, 2016
- Japan Osteoporosis Market to Expand 45.3% by 2024: Fuji Keizai
December 19, 2016
- Public Knowledge-Based Application Filed for Tamiflu’s New Pediatric Dosage
December 19, 2016
- Fujifilm Allies with Russia’s R-Pharm in Healthcare
December 19, 2016
- Otsuka Gets Exclusive Rights to Takara Bio’s Oncolytic Virus in Japan
December 16, 2016
- Continued Xtandi Treatment Fails to Extend PFS: US PIV Trial
December 16, 2016
- Belsomra Most Heavily Promoted Drug in HP Market October: Anterio
December 16, 2016
- Sysmex, Astellas, and Daiichi Sankyo Ink Memo to Create Method for Analyzing CTC
December 16, 2016
- Diovan Data Manipulation Case Closed, Ruling Due Out in March
December 16, 2016
- Shinjiro Sato Tapped as Next President of Terumo
December 16, 2016
- Aspen Japan, Kissei Sign Copromotion Pact on Imuran
December 16, 2016
- Fujifilm to Acquire Takeda’s Reagent Unit for 155 Billion Yen
December 16, 2016
- Nippon Kayaku Introduces “MSLs” to Strengthen Detailing for Oncology Generics, Biosimilars, and Products in Development
December 16, 2016
- Interview: GSK’s New Evaluation System for Sales Reps Helps Deliver Science-Based Message
December 15, 2016
- FunPep, Shionogi Enter Joint Research Agreement for Vaccine Adjuvants
December 15, 2016
- Daiichi Sankyo Aims to File Antibody Drug Conjugate DS-8201 in 2020 for HER2-Positive Breast Cancer, Stomach Cancer
December 15, 2016
- Parkinson’s Med Nouriast Fails in PIII Study in US, Europe: Kyowa Kirin
December 14, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…